Crosslinkable biological material and medical uses

• US 7,101,857 B2
• Filed: 04/19/2004
• Issued: 09/05/2006
• Est. Priority Date: 11/05/1996
• Status: Expired due to Fees

• Current Assignee: GP Medical, Inc.
• Original Assignee: GP Medical, Inc.
• Inventors: Liang, Huang-chien, Sung, Hsing-Wen, Tu, Hosheng
• Primary Examiner(s): Jiang, Shaojia
• Assistant Examiner(s): Krishnan, Ganapathy
• Application Number:
  US10/827,673
• Publication Number:
  US 20050124560A1
• Time in Patent Office: 869 Days
• Field of Search: 514/26, 424/423, 424/445, 435/325
• US Class Current: 514/26
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 2310/00365 Proteins; Polypeptides; Degradation products thereof
• CPC Class Codes: A61F 2310/00383 Gelatin
• CPC Class Codes: A61L 15/28 Polysaccharides or their derivatives A61L15/225 takes precedence
• CPC Class Codes: A61L 15/32 Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin A61L15/225 takes precedence
• CPC Class Codes: A61L 15/325 Collagen
• CPC Class Codes: A61L 24/10 Polypeptides; Proteins A61L24/043 takes precedence
• CPC Class Codes: A61L 24/102 Collagen
• CPC Class Codes: A61L 24/104 Gelatin
• CPC Class Codes: A61L 2430/40 Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
• CPC Class Codes: A61L 26/0023 Polysaccharides
• CPC Class Codes: A61L 26/0033 Collagen
• CPC Class Codes: A61L 26/0038 Gelatin
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 27/22 Polypeptides or derivatives thereof , e.g. degradation products
• CPC Class Codes: A61L 27/222 Gelatin
• CPC Class Codes: A61L 27/24 Collagen
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: C08L 5/08 : Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Abstract

A method for promoting angiogenesis in a patient comprising providing crosslinkable biological solution to the target tissue, wherein the crosslinkable biological solution is loaded with at least one angiogenic agent. In one embodiment, the at least one angiogenic agent is a non-protein factor selected from a group consisting of ginsenoside Rg₁, ginsenoside Re, combination thereof and the like. In another embodiment, the crosslinkable biological solution of the present invention is broadly defined in a form or phase of solution, paste, gel, suspension, colloid or plasma that may be solidifiable thereafter.

Claims

1. A method for promoting angiogenesis in a subject in need thereof, comprising administering to said subject a substrate loaded with therapeutically effective amount of angiogenesis factor selected from the group consisting of isolated ginsenoside Rg₁, isolated ginsenoside Re or combinations thereof, wherein the substrate is an artificial organ selected from the group consisting of biological patch, cardiac tissue anti-adhesion membrane and myocardial tissue, wherein the substrate is crosslinked with an agent selected from the group consisting of genepin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimide, carbodiimides, succinimidyls, diisocyanates, acyl azide, tris(hydroxymethyl)phosphine, ascorbate-copper, glucose-lysine and photo-oxidizers.

2. The method of claim 1, wherein the substrate is configured and formulate for administering to said subject by a route selected from a group consisting of topical administration, percutaneous injection, intravenous injection, intramuscular injection, oral administration, and implantation.

3. The method of claim 1, wherein the substrate is an acellular tissue or a wound dressing.

4. The method of claim 3, wherein the acellular tissue has increased porosity over the substrate by at least 5%.

5. A method for promoting angiogenesis for treating a target tissue of a patient, comprising:

providing crosslinkable biological fluid medium consisting of biopolymers selected from the group of collagen extract, soluble collagen, elastin, gelatin, chitosan, N,O-carboxymethyl chitosan (NOCC) to the target tissue, wherein the crosslinkable biological fluid medium is loaded with at least one angiogenesis factor selected from the group consisting of purified ginsenoside Rg₁, purified ginsenoside Re or combinations thereof.

6. The method of claim 5, wherein the crosslinkable biological fluid medium is in a form of solution, paste, gel, suspension, colloid, or plasma.

7. The method of claim 5, wherein the crosslinkable biological fluid medium is crosslinked with a crosslinking agent or with ultraviolet irradiation.

8. A crosslinkable biological solution kit comprising a first readily mixable crosslinkable biological solution component and a second crosslinker component, selected from the group consisting of genepin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimide, carbodiimides, succinimidyls, diisocyanates, acyl azide, tris(hydroxymethyl)phosphine, ascorbate-copper, glucose-lysine and photo-oxidizers, wherein the first component and the second component are mixed at point of need, wherein said first readily mixable crosslinkable biological solution component is selected from the group consisting of purified ginsenoside Rg₁, purified ginsenoside Re or combinations thereof.